Martínez-Gómez Héctor, Peña-Arriaga Magaly Denise, Sánchez-Chimalpopoca Fernando, Servín-Hernández Carlos Alberto
Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Oncología, Servicio de Tumores Ginecológicos. Ciudad de México, México.
Rev Med Inst Mex Seguro Soc. 2023 Jul 31;61(4):420-426. doi: 10.5281/zenodo.8200105.
Currently, epithelial ovarian cancer is diagnosed in advanced stages (EC IIIC) in 75-80% of cases worldwide. In this group of patients treatment with neoadjuvant chemotherapy is started, followed by interval cytoreduction of residual disease and even require peritonectomy with application of hyperthermic intraperitoneal chemotherapy (HIPEC).
To identify the overall survival and progression-free survival associated with peritonectomy, in patients with peritoneal carcinomatosis secondary to ovarian cancer treated in the oncology gynecology service from January 2009 to January 2019 at the UMAE Hospital de Oncología Centro Médico Nacional Siglo XXI.
Observational, descriptive, cross-sectional, retrospective study, information was obtained from the clinical file of patients treated with peritonectomy with the use of hyperthermic intraperitoneal chemotherapy in the gynecological oncology service from January 2009 to January 2019 at the UMAE Hospital de Oncología Centro Médico Nacional Siglo XXI.
Information was obtained from a total of 36 patients (n=100%), 36.1% received intraperitoneal chemotherapy and 63.8% underwent cytoreduction without the application of intraoperative chemotherapy. The most frequently used drug was cisplatin followed by mitomycin. There was no statistical significance when comparing both groups, however there was a trend in favor of the use of intraoperative chemotherapy by obtaining a greater number of months in terms of overall survival.
Peritonectomy with hyperthermic intraperitoneal chemotherapy is an option in selected patients with advanced stage ovarian cancer in primary and recurrent surgery, as well as in patients with platinum-resistant ovarian cancer.
目前，全球75% - 80%的上皮性卵巢癌患者在晚期（EC IIIC期）被诊断出来。对于这组患者，开始采用新辅助化疗，随后对残留病灶进行间歇性细胞减灭术，甚至需要进行腹膜切除术并应用热灌注腹腔化疗（HIPEC）。
确定在2009年1月至2019年1月于墨西哥国立医学中心西格洛 XXI肿瘤医院肿瘤妇科接受治疗的卵巢癌继发腹膜癌患者中，与腹膜切除术相关的总生存期和无进展生存期。
观察性、描述性、横断面、回顾性研究，从2009年1月至2019年1月在墨西哥国立医学中心西格洛 XXI肿瘤医院肿瘤妇科接受腹膜切除术并使用热灌注腹腔化疗的患者临床档案中获取信息。
共获得36例患者的信息（n = 100%），36.1%接受了腹腔化疗，63.8%在未应用术中化疗的情况下进行了细胞减灭术。最常用的药物是顺铂，其次是丝裂霉素。两组比较时无统计学意义，但在总生存期方面，术中化疗组有获得更多月数的趋势，倾向于使用术中化疗。
对于原发性和复发性手术中晚期卵巢癌的特定患者以及铂耐药卵巢癌患者，腹膜切除术联合热灌注腹腔化疗是一种选择。
